EP1675616A2 - Nouvelles igg3 utiles pour stimuler la phagocytose - Google Patents
Nouvelles igg3 utiles pour stimuler la phagocytoseInfo
- Publication number
- EP1675616A2 EP1675616A2 EP04817229A EP04817229A EP1675616A2 EP 1675616 A2 EP1675616 A2 EP 1675616A2 EP 04817229 A EP04817229 A EP 04817229A EP 04817229 A EP04817229 A EP 04817229A EP 1675616 A2 EP1675616 A2 EP 1675616A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- igg3
- use according
- iggl
- produced
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/34—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the invention relates to chimeric, humanized or human monoclonal antibodies of class IgG3 characterized in that they are produced in a rat myeloma cell line.
- said IgG3 are produced in the line YB2 / 0 (ATCC n ° CRL 1662) or a line derived or modified from YB2 / 0.
- the invention relates to rat myeloma cell lines, in particular YB2 / 0 and derived lines, transfected with one or more vector (s) allowing the expression of a functional IgG3.
- the invention also relates to cells having been transfected with one or more vector (s) described above. These cells are characterized in that they produce IgG3 having the glycosylation profile mentioned above and at least one of the properties a) to d) described above.
- a cell derived from a line described above is also an object of the invention.
- the invention relates to the use of IgG3 described above, in particular of IgG3 expressed in YB2 / 0, for the preparation of a medicament.
- Anti-CD3 antibodies towards clinical antigen-specific immunomodulation. Curr Opin Pharmacol. 2004 Aug; 4 (4): 403- 7; Yamada-Ohnishi Y, Azuma H, Urushibara N, Yamaguchi M, Fujihara M, Kobata T, Ikeda H. Cytotoxic Difference of T Cells Expanded with Anti-CD3 Monoclonal Antibody in the Présence and Absence of Anti- CD28 Monoclonal Antibody. Stem Cells Dev. 2004 Jun; 13 (3): 315-22.).
- Example 3 Measurement by competition of the binding of the three antibodies of Example 1 to Jurkat CD16 cells by flow cytometry.
- the particular glycan profile of PIgG3 produced in YB2 / 0, that is to say, short forms, not sialylated, and with a fucose level of less than 35% gives it original properties as demonstrated above: - strong fixation CD 16 which is comparable to that of IgGl, potentiation of phagocytosis an increase in ADCC activity in the presence of PBMC or NK cells compared to IgG3 produced in CHO. an ability to compete with IgGl at the level of their binding to CD 16 and thus negatively modulate the secretion of cytokines.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- AIDS & HIV (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0312087A FR2861078B1 (fr) | 2003-10-16 | 2003-10-16 | NOUVELLES IgG3 UTILES POUR STIMULER LA PHAGOCYTOSE |
PCT/FR2004/002657 WO2005037866A2 (fr) | 2003-10-16 | 2004-10-18 | Igg3 anti rhesus-d dans la lignee yb2/0 ayant une forte activite en phagocytose |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1675616A2 true EP1675616A2 (fr) | 2006-07-05 |
Family
ID=34385205
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP04817229A Withdrawn EP1675616A2 (fr) | 2003-10-16 | 2004-10-18 | Nouvelles igg3 utiles pour stimuler la phagocytose |
Country Status (9)
Country | Link |
---|---|
US (1) | US20070218052A1 (fr) |
EP (1) | EP1675616A2 (fr) |
JP (1) | JP2007533639A (fr) |
AU (1) | AU2004281220A1 (fr) |
BR (1) | BRPI0415420A (fr) |
CA (1) | CA2542508A1 (fr) |
FR (1) | FR2861078B1 (fr) |
IL (1) | IL174949A0 (fr) |
WO (1) | WO2005037866A2 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005053742A1 (fr) * | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | Medicament contenant une composition a base d'anticorps |
FR2957598B1 (fr) | 2010-03-17 | 2015-12-04 | Lfb Biotechnologies | Nouveau peptide signal, et son utilisation pour la production de proteines recombinantes |
FR3003171B1 (fr) * | 2013-03-15 | 2015-04-10 | Lab Francais Du Fractionnement | Nouveaux medicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5496548A (en) * | 1987-09-18 | 1996-03-05 | National Blood Authority | Human anti-RH(D) monoclonal antibodies, cell lines and methods of use of antibodies in immunoassays |
BR9305557A (pt) * | 1992-06-26 | 1997-03-25 | Aetsrn | Anticorpos monoclonais humanos anti Rhesus-D e composiçao farmacêutica que os contém |
DE10001372A1 (de) * | 2000-01-14 | 2001-08-02 | Deutsches Krebsforsch | Anti-CD3-Einzelketten-Antikörper mit humanem Cmu3- und Cmu4- Domänen |
FR2807767B1 (fr) * | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-d |
US7605235B2 (en) * | 2003-05-30 | 2009-10-20 | Centocor, Inc. | Anti-tissue factor antibodies and compositions |
-
2003
- 2003-10-16 FR FR0312087A patent/FR2861078B1/fr not_active Expired - Fee Related
-
2004
- 2004-10-18 WO PCT/FR2004/002657 patent/WO2005037866A2/fr active Application Filing
- 2004-10-18 BR BRPI0415420-7A patent/BRPI0415420A/pt not_active IP Right Cessation
- 2004-10-18 CA CA002542508A patent/CA2542508A1/fr not_active Abandoned
- 2004-10-18 AU AU2004281220A patent/AU2004281220A1/en not_active Abandoned
- 2004-10-18 JP JP2006534803A patent/JP2007533639A/ja active Pending
- 2004-10-18 EP EP04817229A patent/EP1675616A2/fr not_active Withdrawn
- 2004-10-18 US US10/575,218 patent/US20070218052A1/en not_active Abandoned
-
2006
- 2006-04-11 IL IL174949A patent/IL174949A0/en unknown
Non-Patent Citations (1)
Title |
---|
See references of WO2005037866A2 * |
Also Published As
Publication number | Publication date |
---|---|
WO2005037866A3 (fr) | 2005-07-21 |
FR2861078A1 (fr) | 2005-04-22 |
WO2005037866A2 (fr) | 2005-04-28 |
FR2861078B1 (fr) | 2007-09-21 |
US20070218052A1 (en) | 2007-09-20 |
IL174949A0 (en) | 2006-08-20 |
AU2004281220A1 (en) | 2005-04-28 |
WO2005037866A8 (fr) | 2006-06-01 |
CA2542508A1 (fr) | 2005-04-28 |
JP2007533639A (ja) | 2007-11-22 |
BRPI0415420A (pt) | 2006-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1537147B1 (fr) | Anticorps anti hla-dr ayant une adcc augmentée et induisant la production de cytokines. | |
TWI660972B (zh) | 抗mcam抗體及相關使用方法 | |
EP3159008B1 (fr) | Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs | |
CA2498383C (fr) | Traitement des pathologies echappant a la reponse immune par des anticorps optimises | |
TWI359671B (en) | Cd40 antibody formulation and methods | |
KR101297146B1 (ko) | 인간화 FcγRIIB 특이적 항체 및 그의 사용 방법 | |
CN111727197A (zh) | 抗pd-1抗体和治疗方法 | |
KR20190117489A (ko) | 항-bcma 중쇄-단독 항체 | |
FR2915398A1 (fr) | "ensemble de moyens pour le traitement d'une pathologie maligne, d'une maladie auto-immune ou d'une maladie infectieuse" | |
WO2019115773A1 (fr) | Variants avec fragment fc ayant une affinité augmentée pour fcrn et une affinité augmentée pour au moins un récepteur du fragment fc | |
JP2022516301A (ja) | Cd137アゴニスト性抗体とその使用 | |
EP1675616A2 (fr) | Nouvelles igg3 utiles pour stimuler la phagocytose | |
EP1537419B1 (fr) | Procédé d'évaluation de l'efficacité ADCC médiée par le CD16 d'anticorps monoclonaux ou polyclonaux | |
HUT77342A (hu) | Immunoszupresszív aktivitással rendelkező monoklonális antitest fragmensek | |
CA2542928A1 (fr) | Utilisation de cations metalliques pour cristalliser le fragment fc d'un anticorps rhesus d | |
EP3555133A1 (fr) | Combinaison d'anticorps anti-cd303 et anti-her2 | |
FR2910896A1 (fr) | Anticorps monoclonal dirige contre le recepteur humain des ldl |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20060411 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR |
|
R17D | Deferred search report published (corrected) |
Effective date: 20060601 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: KLEIN, PHILIPPE Inventor name: BIHOREAU, NICOLAS Inventor name: BOUREL, DOMINIQUE Inventor name: JORIEUX, SYLVIE Inventor name: DE ROMEUF, CHRISTOPHE |
|
DAX | Request for extension of the european patent (deleted) | ||
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: LFB BIOTECHNOLOGIES |
|
17Q | First examination report despatched |
Effective date: 20090415 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20090826 |